Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Immune-Mediated Necrotizing Myopathy following mRNA SARS-CoV-2 Vaccination

• Published in: Case reports in neurological medicine Vol. 2023; pp. 7061783 - 5
• Main Authors: Rodrigues de Carvalho, Marta, Sá de Deus Rocha, Myrian Mathildes, Alves Bezerra, Vinícius, de Pontes, Maciel Eduardo, del Negro, Maria Cristina, Antunes, Julio Salgado, Montanaro, Vinícius Viana Abreu, Fernandez, Rubens Nelson Morato
• Format: Journal Article
• Language: English
• Published: United States Hindawi 27.05.2023; Hindawi Limited; Wiley
• Subjects: Biopsy; Case Report; COVID-19 vaccines; Disease transmission; Hepatitis; Hospitals; Kinases; Patients; Public health; Severe acute respiratory syndrome coronavirus 2; Steroids; Tetanus; Tropical diseases
• ISSN: 2090-6668; 2090-6676
• DOI: 10.1155/2023/7061783

The new coronavirus (COVID-19) pandemic has resulted in the unprecedented production of vaccines. In this context, the possible adverse effects remain to be identified and reported. In this article, we report the case of a young female patient who developed anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMG-CoA) immune-mediated necrotizing myositis (IMNM) after receiving the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine. The diagnosis of probable post-vaccination IMNM was made due to the absence of other factors that may have led to the development of autoantibodies (medicines; e.g., statins, drugs) and the temporal relationship between exposure and event. This case report is the first to suggest that a COVID-19 vaccine may trigger anti-HMG-CoA reductase necrotizing myopathy.